South Africa has launched its first domestically developed foot-and-mouth disease (FMD) vaccine, a landmark step in safeguarding livestock health, improving meat supply stability and reducing costly dependence on imported vaccines.

Developed by the government-backed Agricultural Research Council (ARC) in Pretoria, the locally produced vaccine aims to immunise up to 80% of the nation’s roughly 12 million cattle herd — a crucial threshold for controlling FMD outbreaks that have periodically disrupted Southern African farm systems. Distribution will begin with 20,000 doses per week starting March 2026, scaling up to 200,000 doses weekly by 2027 under national roll-out plans.

Officials say greater self-reliance in animal health inputs could lower production costs for commercial and smallholder producers alike, stabilise red meat markets, and enhance export prospects into regional markets where disease-free status is critical.

The timing is strategic: while livestock sectors across Africa confront disease, climate stress and input cost volatility, local vaccine capacity offers a model for other countries striving to secure agricultural supply chains and strengthen food security.

What this means for Africa’s agriculture industry

• Disease risk reduction: A domestically produced FMD vaccine reduces reliance on external suppliers and strengthens national veterinary systems.
• Export resilience: Regional export agreements often demand strict animal health standards — local vaccine production strengthens compliance.
• Cost savings: Reducing import bills for pharmaceuticals can improve cash flow for farm enterprises.

With livestock underpinning livelihoods and nutrition across the continent, South Africa’s vaccine initiative is a notable development for African agribusiness.